Why tyrosine kinase inhibitor resistance is common in advanced gastrointestinal stromal tumors

Background: Most patients with advanced gastrointestinal stromal tumors (GIST) develop drug resistance to tyrosine kinase inhibitors (TKIs) within two years of starting therapy, whereas most chronic myeloid leukemia (CML) patients in chronic phase still exhibit disease control after a decade on ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomasetti, Cristian, Demetri, George D, Parmigiani, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000Research 2013
Materias:
Short Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3892920/
https://www.ncbi.nlm.nih.gov/pubmed/24555070
http://dx.doi.org/10.12688/f1000research.2-152.v1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3892920/
https://www.ncbi.nlm.nih.gov/pubmed/24555070
http://dx.doi.org/10.12688/f1000research.2-152.v1

Ejemplares similares